Tocilizumab for rheumatoid arthritis
Author:
Publisher
John Wiley & Sons, Ltd
Reference57 articles.
1. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose-escalation trial;Choy;Arthritis & Rheumatism,2002
2. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial;Emery;Annals of the Rheumatic Disease,2008
3. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study;Genovese;Arthritis & Rheumatism,2008
4. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate;Maini;Arthritis & Rheumatism,2006
5. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. A multicenter, double-blind, placebo-controlled trial;Nishimoto;Arthritis & Rheumatism,2004
Cited by 58 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Histological Assessment of Respiratory Tract and Liver of BALB/c Mice Nebulized with Tocilizumab;Pharmaceutics;2024-06-27
2. Staphylococcus aureus subcapsular splenic abscess and associated empyema in the setting of tocilizumab therapy: A case report;Clinical Case Reports;2024-05-24
3. Exploring the therapeutic potential of regulatory T cell in rheumatoid arthritis: Insights into subsets, markers, and signaling pathways;Biomedicine & Pharmacotherapy;2024-05
4. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study;International Ophthalmology;2024-04-16
5. Effect of anti-COVID-19 drugs on patients with cancer;European Journal of Medicinal Chemistry;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3